IMMX logo

IMMXImmix Biopharma Inc

$8.10
$0.08
(0.98%)
Today
Closed $8.10
$0.0199
(0.25%)
After Hours
Updated: 07:35 PM EDT
Mkt Cap$582.33M
Vol1.07M
News
all
press releases
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
News Placeholder
More News
News Placeholder
What's Going On With Immix Biopharma Stock Thursday?
Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.read more...
Benzinga
News Placeholder
The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms
Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN
24-7 Market News
News Placeholder
Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6% - Time to Sell?
Immix Biopharma (NASDAQ:IMMX) Shares Down 4.6% - Time to Sell...
MarketBeat
News Placeholder
Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 12% - Still a Buy...
MarketBeat
News Placeholder
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages
Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One...
MarketBeat
News Placeholder
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says
Mizuho raised their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Monday...
MarketBeat
News Placeholder
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results
Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus...
MarketBeat
News Placeholder
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX)
Citizens Jmp restated a "market outperform" rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday...
MarketBeat
News Placeholder
Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright
HC Wainwright lifted their price objective on shares of Immix Biopharma from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.